| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo … C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ... The Lancet 377 (9784), 2181-2192, 2011 | 2931 | 2011 |
| Rosuvastatin and cardiovascular events in patients undergoing hemodialysis BC Fellström, AG Jardine, RE Schmieder, H Holdaas, K Bannister, ... New England Journal of Medicine 360 (14), 1395-1407, 2009 | 2306 | 2009 |
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis RB Jones, JW Cohen Tervaert, T Hauser, R Luqmani, MD Morgan, ... New England Journal of Medicine 363 (3), 211-220, 2010 | 1965 | 2010 |
| 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus A Fanouriakis, M Kostopoulou, A Alunno, M Aringer, I Bajema, JN Boletis, ... Annals of the rheumatic diseases 78 (6), 736-745, 2019 | 1772 | 2019 |
| A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies D Jayne, N Rasmussen, K Andrassy, P Bacon, JWC Tervaert, ... New England Journal of Medicine 349 (1), 36-44, 2003 | 1673 | 2003 |
| EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis M Yates, RA Watts, IM Bajema, MC Cid, B Crestani, T Hauser, B Hellmich, ... Annals of the rheumatic diseases 75 (9), 1583-1594, 2016 | 1339 | 2016 |
| Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of … GK Bertsias, M Tektonidou, Z Amoura, M Aringer, I Bajema, JHM Berden, ... Annals of the rheumatic diseases 71 (11), 1771-1782, 2012 | 1231 | 2012 |
| Genetically distinct subsets within ANCA-associated vasculitis PA Lyons, TF Rayner, S Trivedi, JU Holle, RA Watts, DRW Jayne, ... New England Journal of Medicine 367 (3), 214-223, 2012 | 1064 | 2012 |
| Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial K De Groot, L Harper, DRW Jayne, LF Flores Suarez, G Gregorini, ... Annals of internal medicine 150 (10), 670-680, 2009 | 1035 | 2009 |
| KDIGO 2021 clinical practice guideline for the management of glomerular diseases BH Rovin, SG Adler, J Barratt, F Bridoux, KA Burdge, TM Chan, HT Cook, ... Kidney international 100 (4), S1-S276, 2021 | 813 | 2021 |
| 2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the … A Fanouriakis, M Kostopoulou, K Cheema, HJ Anders, M Aringer, ... Annals of the rheumatic diseases 79 (6), 713-723, 2020 | 677 | 2020 |
| Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis: a randomized controlled trial TF Hiemstra, M Walsh, A Mahr, CO Savage, K De Groot, L Harper, ... Jama 304 (21), 2381-2388, 2010 | 651 | 2010 |
| Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens K Kiryluk, Y Li, F Scolari, S Sanna-Cherchi, M Choi, M Verbitsky, D Fasel, ... Nature genetics 46 (11), 1187-1196, 2014 | 624 | 2014 |
| Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis M Walsh, PA Merkel, CA Peh, WM Szpirt, X Puéchal, S Fujimoto, ... New England Journal of Medicine 382 (7), 622-631, 2020 | 612 | 2020 |
| Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis DRW Jayne, AN Bruchfeld, L Harper, M Schaier, MC Venning, P Hamilton, ... Journal of the American Society of Nephrology 28 (9), 2756-2767, 2017 | 580 | 2017 |
| Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up L Harper, MD Morgan, M Walsh, P Hoglund, K Westman, O Flossmann, ... Annals of the rheumatic diseases 71 (6), 955-960, 2012 | 507 | 2012 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 491 | 2019 |
| Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments R Coppo, S Troyanov, S Bellur, D Cattran, HT Cook, J Feehally, ... Kidney international 86 (4), 828-836, 2014 | 438 | 2014 |
| Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases BH Rovin, SG Adler, J Barratt, F Bridoux, KA Burdge, TM Chan, HT Cook, ... Kidney international 100 (4), 753-779, 2021 | 415 | 2021 |
| Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis K Kiryluk, Y Li, S Sanna-Cherchi, M Rohanizadegan, H Suzuki, F Eitner, ... PLoS genetics 8 (6), e1002765, 2012 | 392 | 2012 |
David JayneProfessor of Clinical Autoimmunity, University of CambridgeBestätigte E-Mail-Adresse bei cam.ac.uk
